NCT00147654

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 830 (planned)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: Male
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).

Conditions

• Urinary Incontinence

Interventions

Type	Name	Description
DRUG	Tolterodine ER 4 mg QD
DRUG	Tamsulosin 0.4 mg QD

Timeline

• Start date: 2004-11-01
• Completion: 2006-05-01
• First posted: 2005-09-07
• Last updated: 2021-01-27

Locations

95 sites across 1 country: United States